Search clinical trials for: Isentress® (Raltegravir, 400 every 12 hours)

Total 200 results

IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain
Pfizer

Completed

Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support

Pneumonia

United States
Acibadem University

Completed

The Effect of Replacement Frequency of Electrodes on Skin in Infant

Infant, Premature

Turkey
Kristine Patterson, MD
Merck Sharp & Dohme LLC

Completed

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

HIV | AIDS

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) (WIP)

HIV-1 Infection
Columbia University
Orthopaedic Scientific Research Foundation

Unknown

Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome

Carpal Tunnel Syndrome

United States
Hartford Hospital
Optimer Pharmaceuticals LLC

Completed

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Clostridium Difficile Infection

United States
Venatorx Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections (CERTAIN-1)

Urinary Tract Infections | Acute Pyelonephritis

United States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Latvia, Mexico, Peru, Romania, Russian Federation, Serbia, Turkey, Ukraine
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Completed

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

Human Immunodeficiency Virus

United States
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
Merck Sharp & Dohme LLC
Covance

Completed

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

HIV Infection
Gilead Sciences

Completed

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

HIV Infection

Canada, Germany, United States, Spain, France, Australia, Puerto Rico, Italy, Belgium, Mexico, Switzerland, Portugal, Netherlands, United Kingdom
Merck Sharp & Dohme LLC

Terminated

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

HIV
St Stephens Aids Trust

Completed

Atripla to Raltegravir Switch Study for CNS Toxicity (SSAT036)

HIV Infection

United Kingdom
University of Toronto
Unity Health Toronto; Maple Leaf Research

Completed

Effects of Intensive cART During Acute/Early HIV Infection

Acute HIV Infection

Canada
Centre de Recherches et d'Etude sur la Pathologie...

Recruiting

HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label (DORAL)

HIV Infections

France
ForSight Vision5, Inc.

Completed

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Terminated

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Viremia | HIV-1 Infection | Treatment Resistant Disorders

France
Emory University
Merck Sharp & Dohme LLC; Abbott

Completed

Kaletra-isentress Treatment Evaluation (KITE)

HIV Infections

United States
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy (Neurepo)

Hypoxic Ischemic Encephalopathy

France
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo

Unknown

The Effect of Chloroquine in the Treatment of Patients With Dengue

Dengue

Brazil
Centre Hospitalier Intercommunal de Toulon La Seyne...
Merck Sharp & Dohme LLC; Abbott

Completed

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients (IntensVIH)

HIV Infections

France
Central Institute of Epidemiology, Moscow, Russia
Merck Sharp & Dohme LLC

Unknown

Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients

HIV Infections | Tuberculosis

Russian Federation
Novartis

Completed

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

Heartburn

United States
ReAlta Life Sciences, Inc.
FGK Clinical Research GmbH

Completed

A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS

Healthy

Germany
Kirby Institute
Merck Sharp & Dohme LLC; amfAR, The Foundation for AIDS Research; Abbott

Completed

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (SECOND-LINE)

HIV Infections

Taiwan, Australia, Argentina, Singapore, India, France, South Africa, Chile, Germany, Hong Kong, Ireland, Malaysia, Mexico, New Zealand, Nigeria, Peru, United Kingdom
Sheba Medical Center

Unknown

Antibiotic Prophylaxis in Prosthetic Breast Reconstructions

Surgical Site Infections

Israel
American Institute for Voice and Ear Research

Terminated

Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

Laryngopharyngeal Reflux

United States
Rockefeller University
Merck Sharp & Dohme LLC; Pfizer; Aaron Diamond AIDS Research Center

Completed

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

HIV Infections

United States
Haukeland University Hospital

Unknown

Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia (CAH)

Adrenal Hyperplasia, Congenital

Norway
Rush University Medical Center
Merck Sharp & Dohme LLC

Withdrawn

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women (ICE-002)

HIV-1 Infections

United States
University of Utah

Terminated

Elucidation of Acid-Induced Pulmonary Inflammation

Asthma | Gastroesophageal Reflux

United States
Novartis

Completed

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

Frequent Heartburn

United States
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

HIV

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Malignant Melanoma
The University of Texas Health Science Center at...
Merck Sharp & Dohme LLC; VA Office of Research and Development; Centers for Disease...

Completed

The Effect of Rifapentine on Raltegravir

Healthy

United States
Groupe d'Etude sur le Risque d'Exposition des Soignants...
Merck Sharp & Dohme LLC

Completed

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

HIV Infections

France
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

HIV Infections
David A Wohl, MD
Merck Sharp & Dohme LLC

Completed

Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)

HIV Infections

United States
Allina Health System

Completed

Raltegravir Kaletra Pharmacokinetics (RAL-KAL)

Healthy

United States
Garden State Infectious Disease Associates, PA
GlaxoSmithKline

Completed

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Healthy

United States
Takeda

Completed

Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]

Acute Stress Ulcer and Acute Gastric Mucosal Lesions
St Stephens Aids Trust

Completed

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

HIV Infections

United Kingdom
Yunnan AIDS Care Center

Unknown

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

HIV Infections | HBV Coinfection

China
Saint Michael's Medical Center
Abbott

Completed

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

HIV Infections

United States
St Stephens Aids Trust
Merck Sharp & Dohme LLC

Completed

Renal Integrase Study

HIV

United Kingdom
Ottawa Hospital Research Institute

Recruiting

The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. (RCPK)

Calcium Supplementation in HIV Patients Using Raltegravir

Canada
AstraZeneca

Completed

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Chronic Obstructive Pulmonary Disease

United States, Germany, Poland, Israel, Bulgaria, Czechia, Hungary, Spain, Ukraine, United Kingdom

3

Subscribe